Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Drug Screening Clear all
Not yet recruiting Phase 2 Interventional

Precision T1D Platform - New Therapies for Cardio-Renal Complications

NCT07594145
View directory record Official record
Conditions
Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
Interventions
Finerenone, Sotagliflozin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 4, 2026, 8:43 AM EDT
Completed Not applicable Interventional

Preventing Childhood Obesity Through Early Guidance

NCT01905072
View directory record Official record
Conditions
Childhood Obesity
Interventions
Education Home Visits
Other
Lead sponsor
Arizona State University
Other
Eligibility
1 Day to 40 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 4, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

NCT03907657
View directory record Official record
Conditions
Von-Hippel Lindau, Kidney Disease, Chronic
Interventions
Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
16 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 4, 2026, 8:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

NCT00648739
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma
Interventions
Samalizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 4, 2026, 8:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development and Piloting an Avatar-based Intervention to Support Patients Undergoing Stem Cell Transplantation

NCT05600101
View directory record Official record
Conditions
Hematopoietic Cell Transplantation
Interventions
Care.Coach
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 4, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

NCT04536077
View directory record Official record
Conditions
Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer
Interventions
CDX-301, CDX-1140, Research blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 4, 2026, 8:43 AM EDT
Completed No phase listed Observational

Validation Study of RETINA-AI Galaxy™, an Automated Diabetic Retinopathy Screening Device

NCT04774822
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions
Color Fundus Photography, Mydriatics Agent, Optical Coherence Tomography (OCT)
Procedure · Drug
Lead sponsor
RETINA-AI Health, Inc.
Industry
Eligibility
22 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 4, 2026, 8:43 AM EDT
Active, not recruiting Phase 1 Interventional

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04963153
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Enfortumab Vedotin, Erdafitinib, Multigated Acquisition Scan
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 4, 2026, 8:43 AM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT05600894
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Venetoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Costa Mesa, California • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 8:43 AM EDT
Completed Phase 2 Interventional

Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease

NCT00397696
View directory record Official record
Conditions
Parkinson Disease
Interventions
[123I] 5-IA
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 4, 2026, 8:43 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors

NCT01813266
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 4, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional

An Outpatient Study Investigating Non-prescription Treatments for COVID-19

NCT04621149
View directory record Official record
Conditions
COVID-19
Interventions
chlorine dioxide, zinc acetate, Famotidine, placebo, lactoferrin, green tea extract
Other · Dietary Supplement · Drug
Lead sponsor
Profact, Inc.
Other
Eligibility
20 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Sep 4, 2026, 8:43 AM EDT
Terminated No phase listed Observational

Hepatitis C in Adults Who Underwent Congenital Heart Surgery Before Screening

NCT00359099
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1980 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 4, 2026, 8:43 AM EDT
Completed No phase listed Observational

Drug Sensitivity and Mutation Profiling

NCT04956198
View directory record Official record
Conditions
Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Wilms Tumor, Sarcoma, Spindle Cell, Sarcoma Rhabdoid, Childhood Sarcoma of Soft Tissue
Interventions
Not listed
Lead sponsor
Florida International University
Other
Eligibility
Up to 21 Years
Enrollment
14 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 4, 2026, 8:43 AM EDT
Completed Not applicable Interventional Results available

A Patient-Centered Intervention to Improve Opioid Safety

NCT02791399
View directory record Official record
Conditions
Opioid Safety, Prescription Opioid Misuse, Chronic Pain
Interventions
ISOP Intervention with the Nurse Care Manager
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 4, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Cardiac Conduction of GSK1349572

NCT00996021
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK1349572 250 mg, Placebo Suspension, Moxifloxacin 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2010 · Synced Sep 4, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dolutegravir Renal Impairment Study

NCT01353716
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 4, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

NCT03552393
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Mircera
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Months to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Loma Linda, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 4, 2026, 8:43 AM EDT
Completed Not applicable Interventional Results available

Circadian Effects of Escitalopram

NCT01214044
View directory record Official record
Conditions
Depression
Interventions
placebo/escitalopram
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 4, 2026, 8:43 AM EDT
Not yet recruiting Not applicable Interventional

HERE: Health Empowerment and Resources After Pregnancy

NCT07701148
View directory record Official record
Conditions
Cardiovascular Health
Interventions
Longitudinal patient navigation, Standard care
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
23 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 4, 2026, 8:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radiotherapy, LHRHa, Apalutamide
Radiation · Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years and older · Male only
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
13
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 8:43 AM EDT
Recruiting Phase 2 Interventional

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

NCT05847569
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 4, 2026, 8:43 AM EDT
Recruiting Not applicable Interventional

Latinos Understanding the Need for Adherence in Diabetes Using E-Health

NCT05570734
View directory record Official record
Conditions
Type 2 Diabetes, Glycemic Control, Psychological Distress
Interventions
LUNA Care Coordination, LUNA Behavioral Health, Health Education Videos, Virtual Integrated Visits
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 4, 2026, 8:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer

NCT07216209
View directory record Official record
Conditions
Lung Cancer - Non Small Cell
Interventions
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 4, 2026, 8:43 AM EDT